Table 1.

Design and outcomes of the studies included in the meta-analysis

Num	Research	Total patients	Median follow-up	SGLT2 inhibitor	EF at baseline	DM status At baseline	Primary outcomes
1	EMPEROR-Preserved	5988	26.2 months	Empagliflozin	EF > 40%	DM/non-DM	Cardiovascular death or hospitalization for heart failure
2	SOLOIST-WHF	256	9.2 months	Sotagliflozin	EF ≥ 50%	DM	Death from cardiovascular causes or hospitalization for HF
3	DELIVER	6263	28.1 months	Dapagliflozin	EF > 40%	DM/non-DM	An unplanned hospitalization for HF or an urgent visit for HF, or cardiovascular death
4	DECLARE-TIMI 58	808	50.4 months	Dapagliflozin	EF > 45%	DM	Cardiovascular death or HF hospitalization
5	VERTIS-CV	1007	36.0 months	Ertugliflozin	EF > 45%	DM	The time to first major adverse cardiovascular event
6	SCORED	1667	16 months	Sotagliflozin	EF ≥ 50%	DM	The first occurrence of a major adverse cardiovascular event

EF = ejection fraction, DM = diabetes mellitus, HF = heart failure, SGLT2 Inhibitor = Sodium-glucose co-transporter 2 inhibitors